Drugs / ICG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02552901 | Nov 2015 → May 2016 | liver failure | Cardiox Corporation | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02552901 ↗ |
| Modality | Diagnostic / imaging agent | “LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function” NCT02552901 ↗ |
| Route | Intravenous | “an indocyanine green (ICG) bolus was injected into a vein” NCT02552901 ↗ |